Record Fourth-Quarter Revenue
Achieved record fourth-quarter revenue of $31.5 million, marking a 12% growth quarter-over-quarter and a 28% year-over-year growth.
Positive Adjusted EBITDA
Delivered positive adjusted EBITDA of $438,000 in the fourth quarter, compared to a loss of $695,000 in the same period in 2023.
Biologics Business Growth
Biologics business grew 21% for the year, driven by new products such as OsteoVide Plus and Ambion.
Cost Reduction Achievements
Reduced operating expenses by approximately $5 million and achieved headcount reductions of more than 13%.
2025 Revenue Guidance
Guidance for 2025 projects revenue growth of 8% to 11%, with expectations of mid-double-digit growth in Biologics.